Psoriasis

被引：558

作者：

Lebwohl, M ^{[1
]}

机构：

[1] CUNY Mt Sinai Sch Med, Dept Dermatol, New York, NY 10029 USA

来源：

LANCET | 2003年 / 361卷 / 9364期

关键词：

D O I：

10.1016/S0140-6736(03)12954-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent breakthroughs in the treatment of psoriasis have led to improved understanding of the pathogenesis of this disease. Activation of T lymphocytes leading to release of cytokines results in proliferation of keratinocytes. Several new biological therapies have been developed, which target specific steps in the pathogenesis of psoriasis. With these new treatments, variable degrees of clearing occur. Initial data suggest improved safety over older agents such as methotrexate and ciclosporin, but long-term data are necessary. Enhancements in topical therapy and phototherapy have also increased the armamentarium of treatments available for this disorder.

引用

页码：1197 / 1204

页数：8

共 105 条

[1] Psoriasis remission time at the Dead Sea [J].

Abels, DJ ;

Harari, M .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :325-326

[2] CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris [J].

Abrams, JR ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Goldfarb, MT ;

Goffe, BS ;

Menter, A ;

Lowe, NJ ;

Krueger, G ;

Brown, MJ ;

Weiner, RS ;

Birkhofer, MJ ;

Warner, GL ;

Berry, KK ;

Linsley, PS ;

Krueger, JG ;

Ochs, HD ;

Kelley, SL ;

Kang, SW .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1243-1252

[3] Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment [J].

Aithal, GP ;

Mansfield, JC .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (08) :1101-1108

[4] Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders [J].

Allen, M ;

Ishida-Yamamoto, A ;

McGrath, J ;

Davison, S ;

Iizuka, H ;

Simon, M ;

Guerrin, M ;

Hayday, A ;

Vaughan, R ;

Serre, G ;

Trembath, R ;

Barker, J .

LABORATORY INVESTIGATION, 2001, 81 (07) :969-976

[5] IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].

Asadullah, K ;

Sterry, W ;

Stephanek, K ;

Jasulaitis, D ;

Leupold, M ;

Audring, H ;

Volk, HD ;

Döcke, WD .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794

[6] Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus [J].

Asumalahti, K ;

Veal, C ;

Laitinen, T ;

Suomela, S ;

Allen, M ;

Elomaa, O ;

Moser, M ;

de Cid, R ;

Ripatti, S ;

Vorechovsky, I ;

Marcusson, JA ;

Nakagawa, H ;

Lazaro, C ;

Estivill, X ;

Capon, F ;

Novelli, G ;

Saarialho-Kere, U ;

Barker, J ;

Trembath, R ;

Kere, J .

HUMAN MOLECULAR GENETICS, 2002, 11 (05) :589-597

[7] Administration of DAB389IL-2 to patients with recalcitrant psoriasis:: A double-blind, phase II multicenter trial [J].

Bagel, J ;

Garland, WT ;

Breneman, D ;

Holick, M ;

Littlejohn, TW ;

Crosby, D ;

Faust, H ;

Fivenson, D ;

Nichols, J .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (06) :938-944

[8] THE PATHOPHYSIOLOGY OF PSORIASIS [J].

BARKER, JNWN .

LANCET, 1991, 338 (8761) :227-230

[9] Genetic aspects of psoriasis [J].

Barker, JNWN .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (04) :321-325

[10]

Barthel HR, 2001, ARTHRIT RHEUM-ARTHR, V45, P404, DOI 10.1002/1529-0131(200108)45:4<404::AID-ART355>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →